Taiwan Liposome Company (TLC) is a clinical-stage pharmaceutical company that specializes in developing and commercializing nanomedicines that use lipid-assembled drug delivery platforms combined with approved active pharmaceutical ingredients. The nanomedicines created by TLC enable faster onset and longer duration of treatment with improved concentration at target tissues and reduced exposure to unwanted systemic effects. Their extensive experience in liposome science has enabled them to create best-in-class nanomedicines that improve the efficacy and safety of treatments for a range of diseases.